Commodore Capital Invests $55M in Amylyx Pharmaceuticals Amid 150% Rally and Upcoming Catalysts

miércoles, 3 de diciembre de 2025, 10:15 am ET1 min de lectura
AMLX--

Commodore Capital has disclosed a new stake in Amylyx Pharmaceuticals, acquiring nearly 4.1 million shares valued at $55 million. Amylyx's stock has rallied 157% over the past year, outperforming the S&P 500. The company is focused on developing therapeutics for neurodegenerative diseases, with lead product AMX0035. With improving fundamentals and upcoming catalysts, investors are optimistic about Amylyx's potential.

Commodore Capital Invests $55M in Amylyx Pharmaceuticals Amid 150% Rally and Upcoming Catalysts

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios